Thursday, December 18, 2025 | 08:48 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

US to pay $1 bn for 1.4 mn more courses of Merck's Covid pill

This brings the total secured courses to 3.1 mn and worth $2.2 bn

Molnupiravir can be given to patients at home, unlike Gilead Sciences Inc.’s antiviral remdesivir and monoclonal antibody therapies, which are administered via an intravenous infusion usually in a hospital or a clinic.
premium

Reuters
The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc and partner Ridgeback Biotherapeutics, the companies said on Tuesday.

The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.

That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.

The drug has been closely watched since data last month showed that when given early in the illness it

Disclaimer: No Business Standard Journalist was involved in creation of this content